Bedoukian   RussellIPM   RussellIPM   Piezoelectric Micro-Sprayer


Home
Animal Taxa
Plant Taxa
Semiochemicals
Floral Compounds
Semiochemical Detail
Semiochemicals & Taxa
Synthesis
Control
Invasive spp.
References

Abstract

Guide

Alphascents
Pherobio
InsectScience
E-Econex
Counterpart-Semiochemicals
Print
Email to a Friend
Kindly Donate for The Pherobase

« Previous AbstractBreath analysis in asbestos-related disorders: a review of the literature and potential future applications    Next AbstractGC-MS Techniques Investigating Potential Biomarkers of Dying in the Last Weeks with Lung Cancer »

Eur Respir J


Title:A breath test for malignant mesothelioma using an electronic nose
Author(s):Chapman EA; Thomas PS; Stone E; Lewis C; Yates DH;
Address:"Inflammation and Infection Research Centre, School of Medical Sciences, University of New South Wales, Sydney, Australia"
Journal Title:Eur Respir J
Year:2012
Volume:20111219
Issue:2
Page Number:448 - 454
DOI: 10.1183/09031936.00040911
ISSN/ISBN:1399-3003 (Electronic) 0903-1936 (Linking)
Abstract:"Malignant mesothelioma (MM) is a rare tumour which is difficult to diagnose in its early stages. Earlier detection of MM could potentially improve survival. Exhaled breath sampling of volatile organic compounds (VOCs) using a carbon polymer array (CPA) electronic nose recognises specific breath profiles characteristic of different diseases, and can distinguish between patients with lung cancer and controls. With MM, the potential confounding effect of other asbestos-related diseases (ARDs) needs to be considered. We hypothesised that as CPA electronic nose would distinguish patients with MM, patients with benign ARDs, and controls with high sensitivity and specificity. 20 MM, 18 ARD and 42 control subjects participated in a cross-sectional, case-control study. Breath samples were analysed using the Cyranose 320 (Smiths Detection, Pasadena, CA, USA), using canonical discriminant analysis and principal component reduction. 10 MM subjects created the training set. Smell prints from 10 new MM patients were distinguished from control subjects with an accuracy of 95%. Patients with MM, ARDs and control subjects were correctly identified in 88% of cases. Exhaled breath VOC profiling can accurately distinguish between patients with MM, ARDs and controls using a CPA electronic nose. This could eventually translate into a screening tool for high-risk populations"
Keywords:Aged Asbestos/metabolism Biomarkers/metabolism Breath Tests/*instrumentation/*methods Carbon/chemistry Case-Control Studies Cross-Sectional Studies Female Forced Expiratory Volume Humans Lung/physiology Lung Diseases/*diagnosis Male Mesothelioma/*diagnosi;
Notes:"MedlineChapman, Eleanor A Thomas, Paul S Stone, Emily Lewis, Craig Yates, Deborah H eng Research Support, Non-U.S. Gov't England 2011/12/21 Eur Respir J. 2012 Aug; 40(2):448-54. doi: 10.1183/09031936.00040911. Epub 2011 Dec 19"

 
Back to top
 
Citation: El-Sayed AM 2024. The Pherobase: Database of Pheromones and Semiochemicals. <http://www.pherobase.com>.
© 2003-2024 The Pherobase - Extensive Database of Pheromones and Semiochemicals. Ashraf M. El-Sayed.
Page created on 21-09-2024